[go: up one dir, main page]

PT3556351T - Composição farmacêutica para melhorar os níveis de ferro no sangue, compreendendo polimaltose de ferro (iii) e outra substância ativa adequada para absorçâo de ferro, selecionada entre folinato de cálcio penta-hidratado, vitamina c ou uma combinação de ambos - Google Patents

Composição farmacêutica para melhorar os níveis de ferro no sangue, compreendendo polimaltose de ferro (iii) e outra substância ativa adequada para absorçâo de ferro, selecionada entre folinato de cálcio penta-hidratado, vitamina c ou uma combinação de ambos

Info

Publication number
PT3556351T
PT3556351T PT193860160T PT19386016T PT3556351T PT 3556351 T PT3556351 T PT 3556351T PT 193860160 T PT193860160 T PT 193860160T PT 19386016 T PT19386016 T PT 19386016T PT 3556351 T PT3556351 T PT 3556351T
Authority
PT
Portugal
Prior art keywords
iron
polymaltose
vitamin
blood
iii
Prior art date
Application number
PT193860160T
Other languages
English (en)
Original Assignee
Ioulia Tseti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ioulia Tseti filed Critical Ioulia Tseti
Publication of PT3556351T publication Critical patent/PT3556351T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/295Iron group metal compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/26Iron; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PT193860160T 2018-04-16 2019-03-22 Composição farmacêutica para melhorar os níveis de ferro no sangue, compreendendo polimaltose de ferro (iii) e outra substância ativa adequada para absorçâo de ferro, selecionada entre folinato de cálcio penta-hidratado, vitamina c ou uma combinação de ambos PT3556351T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20180100160A GR1009597B (el) 2018-04-16 2018-04-16 Φαρμακευτικο σκευασμα για την ενισχυση των επιπεδων σιδηρου στο αιμα, που περιεχει πολυμαλτοζικο σιδηρο (ιιι) και μια δραστικη ουσια επιλεγμενη απο πενταϋδρικο φυλλινικο ασβεστιο, βιταμινη c ή συνδυασμο των δυο, που ενισχυει την απορροφηση σιδηρου

Publications (1)

Publication Number Publication Date
PT3556351T true PT3556351T (pt) 2023-09-12

Family

ID=66102021

Family Applications (1)

Application Number Title Priority Date Filing Date
PT193860160T PT3556351T (pt) 2018-04-16 2019-03-22 Composição farmacêutica para melhorar os níveis de ferro no sangue, compreendendo polimaltose de ferro (iii) e outra substância ativa adequada para absorçâo de ferro, selecionada entre folinato de cálcio penta-hidratado, vitamina c ou uma combinação de ambos

Country Status (14)

Country Link
EP (1) EP3556351B1 (pt)
DK (1) DK3556351T3 (pt)
ES (1) ES2956286T3 (pt)
FI (1) FI3556351T3 (pt)
GR (1) GR1009597B (pt)
HR (1) HRP20231108T1 (pt)
HU (1) HUE063948T2 (pt)
LT (1) LT3556351T (pt)
MA (1) MA49589B1 (pt)
PL (1) PL3556351T3 (pt)
PT (1) PT3556351T (pt)
RS (1) RS64559B1 (pt)
SI (1) SI3556351T1 (pt)
SM (1) SMT202300309T1 (pt)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931441A (en) * 1988-11-09 1990-06-05 Luitpold Pharmaceuticals, Inc. Stabilized aqueous leucovorin calcium compositions
IT1237509B (it) * 1989-10-31 1993-06-08 Magis Farmaceutici Complessi con le ciclodestrine indicati per il trattamento di tutte leforme anemiche da carenza di folati, loro preparazione e relative composizioni farmaceutiche
BRPI0617227A2 (pt) * 2005-10-11 2011-07-19 Bayer Consumer Care Ag mistura de sais de ferro e cobre disfarçando gosto metálico
EP1790356A1 (de) * 2005-11-24 2007-05-30 Vifor (International) Ag Präparat, umfassend Eisen(III)-Komplexverbindungen und redoxaktive Substanz(en)
ITTO20120506A1 (it) 2012-06-12 2013-12-13 Inge Spa Cappuccio per un flacone atto alla conservazione di sostanze da mantenersi separate fino alla loro applicazione.
EP2997968A1 (en) 2014-09-22 2016-03-23 Ioulia Tseti Iron (III) hydroxide complexes with activated glucose syrups and process for preparing same

Also Published As

Publication number Publication date
ES2956286T3 (es) 2023-12-18
PL3556351T3 (pl) 2023-11-27
MA49589A (fr) 2020-05-20
HRP20231108T1 (hr) 2023-12-22
HUE063948T2 (hu) 2024-02-28
SI3556351T1 (sl) 2024-02-29
FI3556351T3 (fi) 2023-10-02
SMT202300309T1 (it) 2023-11-13
GR1009597B (el) 2019-09-16
RS64559B1 (sr) 2023-10-31
DK3556351T3 (da) 2023-09-18
EP3556351A1 (en) 2019-10-23
LT3556351T (lt) 2023-09-25
MA49589B1 (fr) 2023-09-27
EP3556351B1 (en) 2023-08-09

Similar Documents

Publication Publication Date Title
NZ752526A (en) Pyrrolobenzodiazepine conjugates
MY196631A (en) Antibody Agents Specific for Human Cd19 and uses Thereof
PH12016501171A1 (en) Peptidomimetic compounds and antibody-drug conjugates thereof
EA201690265A2 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
MX2020010607A (es) Compuestos y metodos para inhibir el transporte de fosfato.
SG10201902664RA (en) Combination therapy for treating cancer
UA116793C2 (uk) Стабільна фармацевтична композиція з фіксованою дозою, що містить мометазон й олопатадин
PH12021551302A1 (en) COMPOUNDS AND THEIR USE FOR THE TREATMENT OF a1-ANTITRYPSIN DEFICIENCY
MX2022002056A (es) Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina.
WO2015059463A3 (en) Treatment of beta-catenin related diseases8
MX2022011372A (es) Composiciones de zinc-y-pga y metodos para tratar el cancer.
TR201004464A2 (tr) Kemik erimesi için formülasyon.
PT3556351T (pt) Composição farmacêutica para melhorar os níveis de ferro no sangue, compreendendo polimaltose de ferro (iii) e outra substância ativa adequada para absorçâo de ferro, selecionada entre folinato de cálcio penta-hidratado, vitamina c ou uma combinação de ambos
BR112019001130A2 (pt) uso de lactama e composição farmacêutica
DE60019947D1 (de) Vorbeugung von kolorektalkrebs
PH12019502290A1 (en) Therapeutic agent for blood cancer
MX2017017177A (es) Citrato de (4-((3r,4r)-3-metoxitetrahidro-piran-4-ilamino)piperidi n-1-il)(5-metil-6-(((2r,6s)-6-(p-tolil)tetrahidro-2h-piran-2-il)m etilamino)pirimidin-4il) metanona.
PH12020500606A1 (en) Use of functionalized calcium carbonate as active ingredient
GB2592457B (en) Bad odor reduction by Mg complex in deodorant emulsion for aerosols, deodorant comprising the same and use of the deodorant
WO2019035602A3 (ko) 혈액 내 gkn1 단백을 이용하는 위암 진단
ATE444072T1 (de) Prävention von epithelzellkarzinom
PH22014000055Y1 (en) A composition for a vitamin supplement containing calcium, vitamin c and vitamin d3 for better absorption